Diagenomix (formerly YeSSGenomics)
Diagenomix is delivering the first-to-market colon cancer diagnostic test that sub-types a patient’s colon cancer in a way that better personalizes a patient's treatment plan. The test, ColotypeR, is expected to improve patient outcomes and health economics while avoiding costly overtreatment. The firm was started in June 2018 by President Christopher Cali, a 2015 ESTEEM graduate who earned a degree in science-business in 2014; Steven Buechler, a professor in applied and computational mathematics and statistics; and Yesim Gokman-Polar. It is based on research by Buechler and Amanda Hummon, an adjunct associate professor in chemistry and biochemistry.